Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer

Muneaki Shimada, Shinya Sato, Tetsuro Oishi, Hiroaki Itamochi, Junzo Kigawa, Nobuhiro Takeshima, Daisuke Aoki, Yoichi Aoki, Yoshihiro Nambu, Kazunori Ochiai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The standard chemotherapeutic regimen for stage IVB, persistent, or recurrent uterine cervical cancer is platinum-based combination chemotherapy such as cisplatin (CDDP)/paclitaxel and CDDP/nogitecan hydrochloride (NGT, topotecan). Because it is unclear whether the CDDP/NGT combination chemotherapy is tolerable for Japanese patients, we conducted the present study to assess the feasibility of CDDP/NGT combination chemotherapy. Methods: Between June 2012 and April 2014, 15 patients with stage IVB, persistent, or recurrent uterine cervical cancer were enrolled in this study. Patients underwent six cycles of NGT at a dose of 0.75 mg/m2, followed immediately by CDDP at a dose of 50 mg/m2 on day 1 by intravenous infusion, and then NGT at a dose of 0.75 mg/m2 on days 2 and 3. Results: Of 15 patients, 9 patients underwent at least 6 cycles of NGT/CDDP combination chemotherapy. Of a total of 83 cycles, 70 cycles (84.3 %) of NGT/CDDP combination chemotherapy could be continued at the starting dose of NGT (0.75 mg/m2). Grade 3/4 hematological toxicities included leukopenia in 10 patients (66.7 %), neutropenia in 15 (100 %), anemia in 6 (40.0 %), thrombocytopenia in 4 (26.7 %), and febrile neutropenia in 4 (26.7 %). The response rate according to RECIST was 27 % (3/11), with partial response in 3 patients. Conclusions: NGT/CDDP combination chemotherapy may be a tolerable and effective regimen for Japanese patients with stage IVB, persistent, or recurrent uterine cervical cancer. Based on the results of this study, NGT/CDDP combination chemotherapy was approved in Japan in November 2015.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalInternational Journal of Clinical Oncology
DOIs
Publication statusAccepted/In press - 2016 May 3

Keywords

  • Chemotherapy
  • Cisplatin
  • Nogitecan hydrochloride (topotecan)
  • Uterine cervical cancer

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Fingerprint Dive into the research topics of 'Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer'. Together they form a unique fingerprint.

  • Cite this